Immunotherapy “stop and go” and early discontinuation: A viable option in limited resources setting
Journal of Oncology Pharmacy Practice
Published online on April 15, 2026
Abstract
Journal of Oncology Pharmacy Practice, Ahead of Print.
BackgroundImmunotherapy (IO) has transformed cancer treatment, improving survival across various malignancies. However, optimal treatment duration and dosing regimens remain unclear. In low- and middle-income countries like Tunisia, access to IO is ...
BackgroundImmunotherapy (IO) has transformed cancer treatment, improving survival across various malignancies. However, optimal treatment duration and dosing regimens remain unclear. In low- and middle-income countries like Tunisia, access to IO is ...